IP Library Granted Patent US 10,112,934
Granted Patent B2
US 10,112,934 · App. 15/491,035 · Granted Oct 30, 2018

(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Inventors: Doris Riether (Biberach an der Riss, DE); Florian Paul Christian Binder (Maselheim, DE); Henri Doods (Warthausen, DE); Stephan Georg Mueller (Warthausen, DE); Janet Rachel Nicholson (Oberhoefan, DE); Achim Sauer (Ravensburg-Torkenweiler, DE)
Assignee: Centrexion Therapeutics Corporation
C07D417/12C07D261/04C07D261/14C07D413/02C07D413/12C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,112,934
App. No.
15/491,035
Granted
Oct 30, 2018
Kind
B2
Abstract

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Claims (28)

1. A method of treating pain selected from the group consisting of acute pain, visceral pain, and neuropathic pain, comprising administering to a human being an effective amount of a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof, to treat the pain.

2. The method of claim 1 , wherein the compound is

3. The method of claim 1 , wherein the pain is acute pain.

4. The method of claim 2 , wherein the pain is acute pain.

5. The method of claim 3 , wherein the acute pain is trigeminal neuralgia.

6. The method of claim 4 , wherein the acute pain is trigeminal neuralgia.

7. The method of claim 1 , wherein the pain is visceral pain.

8. The method of claim 2 , wherein the pain is visceral pain.

9. The method of claim 1 , wherein the pain is neuropathic pain.

10. The method of claim 2 , wherein the pain is neuropathic pain.

11. The method of claim 9 , wherein the neuropathic pain is post-herpetic neuralgia.

12. The method of claim 10 , wherein the neuropathic pain is post-herpetic neuralgia.

13. The method of claim 9 , wherein the neuropathic pain is due to multiple sclerosis.

14. The method of claim 10 , wherein the neuropathic pain is due to multiple sclerosis.

15. The method of claim 9 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.

16. The method of claim 10 , wherein the neuropathic pain is due to chemotherapy caused nerve injury.

17. The method of claim 9 , wherein the neuropathic pain is due to central nervous system injury.

18. The method of claim 10 , wherein the neuropathic pain is due to central nervous system injury.

19. The method of claim 1 , wherein the compound is administered in the form of a tablet, pill, or capsule.

20. The method of claim 3 , wherein the compound is administered in the form of a tablet, pill, or capsule.

21. The method of claim 9 , wherein the compound is administered in the form of a tablet, pill, or capsule.

22. A method of treating complex regional pain syndrome type I, comprising administering to a human being an effective amount of a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof, to treat the complex regional pain syndrome type I.

23. The method of claim 22 , wherein the compound is

24. A method of treating pain due to osteoarthritis, comprising administering to a human being an effective amount of a compound selected from the group consisting of

and a pharmaceutically acceptable salt thereof, to treat the pain due to osteoarthritis.

25. The method of claim 24 , wherein the compound is

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 073683/0099 →
SECURITY INTEREST Recorded Nov 21, 2025
From: CENTREXION THERAPEUTICS CORPORATION
To: ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 073683/0108 →
SECURITY INTEREST Recorded Jul 12, 2023
From: CENTREXION THERAPEUTICS CORPORATION
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 064256/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2018
From: RIETHER, DORIS; BINDER, FLORIAN PAUL CHRISTIAN; DOODS, HENRI; MUELLER, STEPHAN GEORG; NICHOLSON, JANET RACHEL; SAUER, ACHIM
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 046895/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2018
From: RIETHER, DORIS; BINDER, FLORIAN PAUL CHRISTIAN; DOODS, HENRI; MUELLER, STEPHAN GEORG; NICHOLSON, JANET RACHEL; SAUER, ACHIM
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 046993/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2018
From: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 046765/0525 →
Priority Claims (1)
EP 13168165 · May 17, 2013 · regional
Continuity (2)
Continuation 14891051
Related Publication 20170320868A1 · Nov 9, 2017
Cited By (1)
US 12,344,601